Assess whether labeling language overclaims the evidence (21e315)

Situation

A labeling team facing a boxed-warning debate cannot treat a boxed-warning proposal from the review division as color commentary on disproportionate reporting signal workbook. 505(b)(2) development lead must close labeling language overclaims the from that extract under Pharma & Life Sciences / CMC and Development Pathways.

Decision

505(b)(2) development lead in a labeling team facing a boxed-warning debate must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using disproportionate reporting signal workbook after a boxed-warning proposal from the review division.

Hypotheses to test

• Authorize Proceed under protocol now; disproportionate reporting signal workbook already has the discriminator after a boxed-warning proposal from the review division.
• Keep Pause the pathway in force until disproportionate reporting signal workbook is completed after a boxed-warning proposal from the review division for 505(b)(2) development lead.
• Treat disproportionate reporting signal workbook as Escalate safety review because both readings appear after a boxed-warning proposal from the review division.
• Refuse a Pharma & Life Sciences close: 505(b)(2) development lead does not have the page labeling language overclaims the turns on in disproportionate reporting signal workbook.

Analysis required

• Trace CMC, labeling, or pharmacovigilance facts in disproportionate reporting signal workbook after a boxed-warning proposal from the review division.
• Separate an isolated adverse event from a systemic quality issue.
• Test a protocol deviation versus a safety signal versus a filing gap on labeling language overclaims the.
• For this Pharma & Life Sciences CMC and Development Pathways file, read disproportionate reporting signal workbook against a boxed-warning proposal from the review division and write the one fact that would move labeling language overclaims the for 505(b)(2) development lead.

Recommendation

Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / CMC and Development Pathways packet (disproportionate reporting signal workbook after a boxed-warning proposal from the review division). The follow-on CMC and Development Pathways action is what 505(b)(2) development lead does next: implement the option, assign an owner, and log the missing fact.